Predicting the antibiotic susceptibility phenotype from genomic data is challenging, especially for 29 some specific antibiotics in Enterobacteriaceae. Here we aimed to assess the performance of whole 30 genomic sequencing (WGS) for predicting the antibiotic susceptibility in various Enterobacteriaceae 31 species using the detection of antibiotic resistance genes (ARGs), specific mutations and a 32 knowledge-based decision algorithm. We sequenced (Illumina MiSeq 2x250b) 187 clinical isolates 33 from species possessing (n=98) or not (n=89) an intrinsic AmpC-type cephalosporinase. Antibiotic 34 susceptibility was performed by the disc diffusion method. Reads were assembled by A5-miseq and 35
Introduction 50
Whole genome sequencing (WGS) of bacterial strains has now become the gold standard for the 51 identification of antibiotic resistance determinants that includes antibiotic resistance genes (ARGs) 52 and intrinsic genes in which mutational events can lead to antibiotic resistance. Yet, the in silico 53 translation from genotype to phenotype may be challenging because it relies on the quality and 54 exhaustiveness of the available knowledge about the genomic determinants of resistance. First, the 55 ARG database must be exhaustive so that no ARG shall be missed. Several ARG databases have 56 been released over the last decade (1) , the most popular ones being ResFinder (2) and CARD (3). To 57 date, there is no consensus on which database should be used for inferring antibiotic susceptibility 58 phenotype from WGS data. Then, the resistance pattern conferred by the ARGs needs to be known, 59
which is not the case for some variants that have not been experimentally tested (i.e. mutations of 60 unknown phenotypic significance). Of note, no database includes phenotypic data associated with the 61 ARG sequence and the resistance phenotype conferred by the presence of an ARG must be inferred 62 from literature. Even more incomplete are the data relative to the mutational events associated with 63 antibiotic resistance such as those leading to a decreased affinity for the antibiotic (e.g. mutations in 64 the topoisomerase for fluoroquinolone resistance), an increased expression of an intrinsic resistance 65 gene (e.g. blaAmpC in Enterobacteriaceae) and/or a decreased expression of a gene (e.g. oprD in 66 when expressed at a basal level, confers a low-level resistance to beta-lactams. The ampC-81 repression mechanism involves AmpD (an amidase) and AmpR (a transcriptional regulator encoded 82 by the gene located right upstream of ampC). A few studies have reported that the induction of ampC 83 expression could be due to mutational events compromising the functions of AmpD and/or AmpR 84 (20). The resulting AmpC overproduction causes resistance to all beta-lactams except the so-called 85 fourth generation cephalosporins (cefepime) and carbapenems. Still, the census of genetic events 86 leading to an overproduction of AmpC in the context of inferring antibiotic susceptibility from WGS 87 data has not been performed. 88
The use of WGS to infer antibiotic susceptibility could be translated in the clinical setting through 89 clinical metagenomics (CMg), which refers to the metagenomic sequencing the nucleic acid from 90 clinical samples in order to obtain information of clinical relevance. CMg is an emerging field that 91 could transform the way infectious diseases are currently diagnosed. Indeed, CMg applied to various 92 clinical samples has shown promising results in the identification of bacterial pathogens, including the 93 hardly culturable ones. The identification of ARGs and the inference of antibiotic susceptibility should 94 be the next step to achieve for CMg in order to provide a complete bacteriological analysis. CMg can 95 readily be performed in 48-72h using Illumina sequencing platforms, which is a reasonable turn-96 around time when it comes to the bacteriological diagnostic of non-severe infections. As for severe 97 infections such as hospital-acquired pneumonia (HAP), an early identification of infection-causing 98 bacteria and the inference of its antibiotic susceptibility pattern should improve the patient's care in 99 providing an optimized antibiotic regimen. In this perspective, the fast turn-around time offered by 100
Oxford Nanopore Technologies sequencers makes the use of CMg in severe infections such as HAP 101 possible (21). 102
The main bacteria causing HAP are S. aureus, P. aeruginosa and Enterobacteriaceae (22). As the 103 antibiotic susceptibility inference by WGS has already been studied for P. aeruginosa and S. aureus 104 but only for two Enterobacteriaceae species (E. coli and K. pneumoniae), here we aimed at assessing 105 the performances of WGS to infer the susceptibility of various species of Enterobacteriaceae to the 106 antibiotics commonly used in probabilistic therapy of HAP. 107 A total of 187 Enterobacteriaceae strains from the bacteriology laboratory of the Geneva University 111 Hospitals (HUG) have been analyzed for this project (Supplementary Figure 1 ). The strains have 112 been selected according to the following criteria: (1) Enterobacteriaceae species underrepresented in 113 genotype-to-phenotype studies (i.e. Enterobacteriaceae other than E. coli and K. pneumoniae), and 114
(2) strains with an antibiotic susceptibility profile of interest (with the aim of recovering a high diversity 115
of antibiotic susceptibility profiles). Only one strain per patient was selected. Strain identification was 116 performed using matrix-assisted desorption ionization-time of flight mass spectrometry (MALDI-TOF 117 MS; Maldi Biotyper compass, Bruker Daltonics, Bremen, Germany) according to the manufacturer's 118
instructions. 119
The antibiotic susceptibility testing was performed using the disk-diffusion test methods according to 120 the European Committee on Antimicrobial Susceptibility Testing (EUCAST v6.0) methods. The 121 antibiotics considered for this study were penicillins (amoxicillin, piperacillin), penicillins+beta-122 lactamases inhibitors (co-amoxiclav, piperacillin-tazobactam), cephalosporins (ceftazidime and 123 cefepime), carbapenems (meropenem), aminoglycosides (gentamicin and amikacin) and 124 fluoroquinolones (norfloxacin). 125 quality filter. Species identity was verified using MetaPhlAn2 (25). Quality reads were assembled 140 using the A5-miseq assembler (26) (version 20160825:243). Genes were predicted and annotated 141 using PROKKA (27). Antibiotic resistance genes were sought using Diamond (28) and the ResFinder 142 database, accessed October 2017 (2). The threshold for ARG positive detection was arbitrarily set at 143 an h-value (defined as the product of the amino acid identity and the query coverage) ≥0.64. The 144 amino-acid sequences of TEM and SHV beta-lactamases were respectively aligned with those of 145 TEM-1 and SHV-1 in order to identify putative mutations and to assign the variant number according 146 to the numbering scheme of the Lahey Clinic (now hosted by the NCBI). The amino acid sequences 147 of the chromosomal genes associated with quinolone resistance (gyrA and parC) were aligned to the 148 homologous protein sequence from the corresponding species (obtained from the NCBI reference 149 genome) using MUSCLE (29). The ampC promoter region of E. coli was also analyzed for the 150 presence of mutations (19). The results of the assembly process are shown in the Supplementary 151 To determine links between genotype and phenotype, we applied specific rules related to the species, 158 the presence of ARGs and the antibiotic ( Table 1) . We assumed that all the ARGs found in the strains 159 were expressed except for some chromosomal ARGs (Table 1 ). In some cases, we considered that 160 no inference could be performed because of the lack of data regarding the expression level of the 161 ARG (e.g. blaTEM-1 and co-amoxiclav/piperacillin-tazobactam), and therefore no antibiotic-resistance 162 prediction was attempted. A very major error (VME) was defined as inferring susceptibility from 163 genomic data while the strain was actually resistant by phenotypic tests. A major error (ME) was 164 defined as inferring resistance from genomic data while the strain was actually susceptible by 165 phenotypic tests. In case of VMEs for beta-lactams inference, other beta-lactamases were searched 166 in the ResFinderFG database (https://cge.cbs.dtu.dk/services/ResFinderFG/). The spectrum of activity
Results 170

Genotype-to-phenotype inference 171
The analysis of the genomic sequence of 187 strains revealed 1,055 ARGs with 133 being unique. 172
The distribution of the ARGs according to the antibiotic family they confer resistance to is depicted in 173 the Figure 1 . The main ARG families were beta-lactamases (n=225), Tet (efflux and protection, 174 n=220) and AMEs (n=177). Overall, 1,870 isolate-antibiotic combinations were considered (Table 2) . 175
In 295 cases (15.8%) no attempt of antibiotic resistance prediction was made. Attempts were less 176 frequent in AmpC-producing than in non-producing isolates ( Table 3 . 184 185
Penicillins and combination penicillins with beta-lactamase inhibitor 186
In total, 225 beta-lactamases were identified, 52 being unique (Supplementary Figure 5 ). The most 187 common were CTX-M-15 and TEM-1. The correct rates of prediction were 98.9% for amoxicillin, 188 86.1% for co-amoxiclav, 55.6% for piperacillin and 37.4% for piperacillin-tazobactam ( Figure 2 ). For 189 penicillins, two VMEs (but no MEs) were found. The strain P. mirabilis 75 was resistant to penicillins, 190 penicillins+beta-lactamases inhibitors and to extended-spectrum cephalosporins (but ceftriaxone) by 191 phenotypic tests, however, no beta-lactamases or mutations on penicillin-binding proteins (PBP) were 192 identified during the genome analysis (data not showed). The other VME, found in P. mirabilis 122, 193 was due to the absence of a blaHMS-1 beta-lactamase from the current version of ResFinder (although 194 it is listed in ResFinderFG). Finally, 6 VMEs for co-amoxiclav and 5 to piperacillin-tazobactam were 195 likely due to the overexpression of chromosomal beta-lactamases (SHV-1, OXY-1, HUGA) and again 196 to the peculiar phenotype of P. mirabilis 75. 197 spectrum (26 CTX-M, 1 TEM-130 and 1 TEM-138). In all non-AmpC strains (n=98), the inference of 201 ceftazidime susceptibility could be attempted. A correct inference was obtained in 95/98 (96.9%) 202 cases ( Figure 2) , leaving 3 VMEs: two K. pneumoniae isolates with a putative overexpression of SHV-203 1 (31) and P. mirabilis 75. In AmpC strains, the inference of ceftazidime susceptibility could be 204 attempted in only 7/89 cases (7.9%). The prediction was correct in 6/7 cases, with one major error (an 205
Enterobacter aerogenes with a truncated ampD gene, yet susceptible to ceftazidime). 206
For cefepime and meropenem, the prediction could be performed for all strains. A correct inference 207 was achieved in 97.9% (183/187) of strains ( Figure 2) . Four VMEs were observed for cefepime, 208
including P. mirabilis 75 (see explanation above), E. coli 53 (combination of a CMY-42 and a OXA-209 181, both not being reported to alter cefepime susceptibility), Enterobacter cloacae 5 and E. 210 aerogenes 240 (with likely combined overexpression of their chromosomal AmpC and decreased 211 outer membrane permeability). As for meropenem, 5 carbapenemases were identified: 2 OXA-48, 1 212
OXA-181, 1 NDM-1 and 1 NDM-5. Only one VME was found for the same E. aerogenes 240 and a 213 correct inference could be performed in 99.5% (186/187) strains ( Figure 2) . 214
In all, we identified 10 strains with at least a VME (with strains P. mirabilis 75 having 6 VMEs) and 1 215 with one ME, leaving 177/187 strains (94.7%) with a correct prediction for the tested beta-lactams. 216
217
Aminoglycosides 218
We studied genotype-phenotype associations for two aminoglycoside antibiotics, gentamicin and 219 amikacin. Resistance to aminoglycosides is due to the acquisition of AMEs (phosphotransferases 220
[APH], nucleotidyltransferases [ANT] and acetyltransferases [AAC]) and 16S rRNA 221 methyltransferases (e.g. Arm, RmtB). We identified 177 AMEs and one 16S rRNA methyltransferase, 222 with 24 being unique (Supplementary Figure 6) . For gentamicin, all predictions were correct ( Figure  223 2). For amikacin, only MEs were observed ( Figure 2) . Indeed, 13 strains (5 K. pneumoniae, 4 C. The main result of this study is the overall high rate of correct predictions of antibiotic susceptibility 245 from WGS data when predictions were attempted, with a 97.6% concordance rate between 246 phenotypic testing and genotypic results. The results obtained in non-AmpC strains were similar to 247 those already published for E. coli (8-11) and K. pneumoniae (9, 13), and so were the results 248 obtained with AmpC-producing strains when the inference was attempted. However, the prediction of 249 the overexpression of AmpC from genomic data will require more data in order to be effective. Indeed, 250
we found that only a minority of AmpC-producing strains had ampD and ampR genes sharing a high 251 identity with that of the reference genome, which highlights the need for sequencing more strains from 252
AmpC-producing species in order to cover their genetic diversity. 253
For amikacin, WGS could even be more accurate in detecting resistance than conventional testing. 254
The EUCAST guidelines recommend to interpret as non-susceptible to amikacin a strain which is 255 resistant to tobramycin but apparently susceptible to gentamicin and amikacin, i.e. suggesting the 256 production of an AAC(6')-I enzyme (35). Nonetheless, the application of this recommendation is 257 compromised by the co-production of an AAC(3)-II) which confers resistance to gentamicin (13 strains in our study, we observed 13 MEs for amikacin-susceptible phenotype associated with the presence 260 of an AAC(6')-I. In this case, the detection of ARGs and the subsequent phenotype interpretation 261 could be more efficient than conventional testing. Besides, we found no errors in the prediction of 262 susceptibility to gentamicin. 263
We observed a total 23 VMEs in our set of 187 strains. VMEs may cause a failure in the treatment of 264 patients since antibiotics inferred to be active on a pathogenic strain may have no effect. The majority 265 of VMEs occurred for beta-lactams and could be tentatively attributed to an overexpression of 266 chromosomal genes (blaSHV in K. pneumoniae, blaOXY in K. oxytoca, blaHugA in Proteus vulgaris, 267 blaAmpC and loss of permeability in E. cloacae), which addresses the limits of WGS when addressing 268 the levels of expression of ARGs. However, when the increased gene expression is due to gene 269 multiplication, the use of long reads can possibly resolve this issue (36) . Otherwise, we need more 270 data linking mutations to the expression of ARGs and mutations affecting the expression of intrinsic 271 genes such as blaAmpC, or to use naive methods such as machine learning-based methods (15). To 272 the best of our knowledge, the quantification of the expression of genes (e.g. via transcriptomics) for 273 inferring antibiotic susceptibility has not been tested yet for Enterobacteriaceae. One VME was due to 274 the incompleteness of the ResFinder database (absence of the class A beta-lactamase blaHMS-1 275 sequence). The VME in P. mirabilis 75 was left unexplained. Finally, the E. coli strain 53, which 276 produced a CMY-42 and an OXA-181 was resistant to cefepime. CMY-42 is a derivative of CMY-2 277 with a higher activity on cefotaxime and ceftazidime, but its activity on cefepime remains unclear (37) . 278
Of note, the chromosomal blaAmpC of the strain was wild type (data not shown). The decreased 279 susceptibility to cefepime of E. coli 53 could then be explained by the combination of the CMY-42 and 280 OXA-181, the latter having a moderate activity against cefepime (38)). 281
Our study has limitations. We analyzed a limited number of strains per species, and our panel may 282 not be representative of the every-day situation in clinical laboratories. We focused on various 283 resistance profiles for E. coli and K. pneumoniae, while more wild-type strains were included for other 284 species such as Citrobacter koseri and P. vulgaris. The predictive values of WGS for inferring 285 susceptibility indeed depend on the local epidemiology and they were not calculated here. Also, we 286 only considered the antibiotics given in the early stages of HAP, and furthermore we identified 287 situations where we chose not to infer susceptibility from genomic data. Hence, we acknowledge that performant due to intrinsic limitations of WGS, but that in the majority of situations the inference could 290 be attempted with good performances. 291
Clinical metagenomics is expected to reach diagnostic laboratories in the coming years. In the context 292 of HAP, clinical metagenomics has the potential to decrease the turn-around time from sample to 293 results and to definitive antibiotic therapy, potentially providing higher chances of cure or a better 294 outcome. Hence, we chose to consider only a limited set of antibioticsthose used in the context of 295 HAP treatment. We also chose to avoid inference attempts when available data would not support a 296 strong prediction (essentially due to gene expression unpredictability), leaving some uncertainty for 297 some species-antibiotic combination. From this clinical perspective, we observed very good 298 performances for ceftazidime (in non-AmpC producing strains), cefepime (all strains), 299 fluoroquinolones and aminoglycosides, with rare VMEs in our set. Our results support that clinical 300 metagenomics could allow a reliable antibiotic susceptibility prediction for relevant antibiotics in the 301 HAP context, provided that a good genome coverage of the bacterial pathogen would be achieved. -Intrinsic AmpC-producing species were considered to be resistant to AMX and AMC.
-Intrinsic penicillinase-producing species (Klebsiella pneumoniae , Klebsiella oxytoca , Citrobacter koseri ) were Ceftazidime For non-AmpC species: strains were considered to be susceptible to CAZ when no ESBL or carbapenemase (other than OXA-48-like) -encoding gene was found. For E. coli , strains were considered to be susceptible to CAZ when no -42C>T and -18G>A, and/or the -32T>A were found. For other AmpC-species: strains were considered to be susceptible to CAZ when both AmpD and AmpR had no mutation compared to the reference AmpD and AmpR proteins, and no ESBL or carbapenemase (other Cefepime Strains were considered to be susceptible to FEP when no ESBL or carbapenemase (other than OXA-48-like)encoding gene was found.
Meropenem
Strains were considered to be susceptible to MEM when no carbapenemase-encoding gene was found. Gentamicin Providencia stuartii strains were considered to be resistant to GEN. Strains were considered to be resistant to GEN when an AAC(3) or a 16S rRNA methylase-encoding gene was found. Amikacin Serratia marcescens strains were considered to be resistant to AMK. Strains were considered to be resistant to AMK when an AAC(6')-I and/or an APH(III)-VI and/or a 16S rRNA methylase was found. Norfloxacin Strains were considered to be resistant to NOR when: -at least one mutation was found in the quinolone resistant determining region (QRDR) of GyrA and/or ParC -and/or an acquired Qnr was found. Species with an intrinsic qnr gene (Citrobacter freundii , Serratia marcescens ) were considered to be susceptible to NOR. Species with an intrinsic OqxAB efflux system (Klebsiella pneumoniae , Klebsiella oxytoca , Enterobacter aerogenes , Enterobacter cloacae , Serratia marcescens ) were considered to be susceptible to NOR. 
